Mobile

A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to tr...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001574-28

A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part A: • To assess the safety and tolerability (incidence and severity of adverse events [AEs]) of the combination of AT13387 and abiraterone acetate and to select the most promising treatment regimen for the combination in subjects with castration-resistant prostate cancer (CRPC) who are no longer responding to treatment with abiraterone acetate alone, based on the overall assessment of safety and antitumor activity. Part B: • To assess and compare the antitumor activity (response rate per the Prostate Cancer Working Group 2 [PCWG2] recommendations) between single-agent AT13387 and the combination of AT13387 plus abiraterone acetate in subjects who are no longer responding to treatment with abiraterone acetate alone.

Critère d'inclusion

  • Castration-resistant prostate cancer (CRPC)

Liens